Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial
Debu Tripathy(The University of Texas MD Anderson Cancer Center), Yen‐Shen Lu(National Taiwan University Hospital), Iván Díaz-Padilla(Center for Global Development), Nadia Harbeck(Breast Center), Joohyuk Sohn(Yonsei University), Samit Hirawat(Novartis (United States)), Aditya Bardia(UCLA Health), Keun Seok Lee(Inserm), Saúl Campos-Gómez(National Cancer Center), Kyung Hae Jung(University of Ulsan), Paul Wheatley‐Price(University of Ottawa), Marco Colleoni(European Institute of Oncology), Sherko Küemmel(Kliniken Essen-Mitte), Govind Babu(Kidwai Memorial Institute of Oncology), Gareth Hughes(University of Greater Manchester), Sara A. Hurvitz(University of Washington), Seock‐Ah Im(Seoul National University), Fábio Franke(National Cancer Center), Rafael Villanueva-Vázquez(National Cancer Center), Young‐Hyuck Im(Samsung (South Korea)), Nagi S. El-Saghir(American University of Beirut Medical Center), Louis W.C. Chow(National Cancer Center), Gary P. Carlson(Novartis (United States)), Caroline Germa(Novartis (United States)), Mei-Ching Liu(Koo Foundation Sun Yat-Sen Cancer Center), Michelino De Laurentiis(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale")
Cited by 1,008
Related Papers
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k